Edition:
United Kingdom

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

2,815JPY
22 May 2019
Change (% chg)

¥139 (+5.19%)
Prev Close
¥2,676
Open
¥2,716
Day's High
¥2,825
Day's Low
¥2,710
Volume
224,100
Avg. Vol
194,451
52-wk High
¥5,210
52-wk Low
¥2,506

Latest Key Developments (Source: Significant Developments)

GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - GNI Group Ltd <2160.T>:Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA.  Full Article

GNI Group gets IND clearance by FDA for liver fibrosis treatment
Monday, 9 Oct 2017 

Oct 9 (Reuters) - GNI Group Ltd <2160.T>:GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis.‍GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017​.‍GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018​.Preliminary results are expected within 2018​.  Full Article

GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis
Monday, 2 Oct 2017 

Oct 2(Reuters) - GNI Group Ltd <2160.T>:Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis.  Full Article